lorcaserin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4374 616202-92-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lorcaserin hydrochloride hemihydrate
  • lorcaserin hydrochloride
  • belviq
  • lorcaserin
  • lorcaserin HCl
  • APD356
  • APD 356
  • APD-356
a serotonin 2C receptor agonist for oral administration used for chronic weight management
  • Molecular weight: 195.69
  • Formula: C11H14ClN
  • CLOGP: 3.24
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -3.44
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 27, 2012 FDA EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Headache 131.85 36.20 104 1123 478248 46206587
Dizziness 88.76 36.20 72 1155 340342 46344493
Fatigue 81.99 36.20 89 1138 608608 46076227

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC A08AA11 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000185009 Serotonin 2c Receptor Agonists
FDA EPC N0000185010 Serotonin-2c Receptor Agonist
CHEBI has role CHEBI:74518 anti-obestic agent
CHEBI has role CHEBI:35941 serotonergic agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Obesity indication 414916001 DOID:9970
Pregnancy, function contraindication 289908002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2C GPCR AGONIST Ki 7.89 DRUG LABEL DRUG LABEL
5-hydroxytryptamine receptor 2B GPCR Ki 6.83 DRUG LABEL
5-hydroxytryptamine receptor 2A GPCR Ki 7.04 DRUG LABEL
Sodium-dependent serotonin transporter Transporter Ki 5.58 CHEMBL

External reference:

IDSource
D06613 KEGG_DRUG
4032466 VUID
N0000187068 NUI
856681-05-5 SECONDARY_CAS_RN
4032466 VANDF
4032467 VANDF
C2350946 UMLSCUI
CHEBI:66852 CHEBI
CHEMBL2095211 ChEMBL_ID
CHEMBL360328 ChEMBL_ID
11673085 PUBCHEM_CID
DB04871 DRUGBANK_ID
C506658 MESH_SUPPLEMENTAL_RECORD_UI
2941 IUPHAR_LIGAND_ID
8765 INN_ID
637E494O0Z UNII
1300700 RXNORM
191544 MMSL
244047 MMSL
28610 MMSL
d07875 MMSL
015054 NDDF
015055 NDDF
716226007 SNOMEDCT_US
716227003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Belviq HUMAN PRESCRIPTION DRUG LABEL 1 62856-529 TABLET 10 mg ORAL NDA 32 sections
BELVIQ XR Extended ReleaseExtended Release HUMAN PRESCRIPTION DRUG LABEL 1 62856-535 TABLET, FILM COATED, EXTENDED RELEASE 20 mg ORAL NDA 31 sections